Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.

被引：12

作者：

Advani, Ranjana H.

Flinn, Ian

Popplewell, Leslie

Forero-Torres, Andres

Bartlett, Nancy L.

Ghosh, Nilanjan

Kline, Justin Paul

Tran, Thu

Lynn, Judith

Chen, James Y.

Agoram, Balaji

Huang, Jenny

Takimoto, Chris H. M.

Chao, Mark

Smith, Sonali M.

机构：

[1] Stanford Canc Inst, Stanford, CA USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] City Hope Natl Med Ctr, Duarte, CA USA

[4] Univ Alabama Birmingham, Birmingham, AL USA

[5] Washington Univ, Sch Med St Louis, Washington, DC USA

[6] Siteman Canc Ctr, St Louis, MO USA

[7] Carolinas Healthcare, Charlotte, NC USA

[8] Univ Chicago Hosp, Chicago, IL USA

[9] Stanford Univ, Sch Med, Stanford, CA USA

[10] Forty Seven Inc, Menlo Pk, CA USA

[11] Univ Chicago, Hematol Oncol Sect, Chicago, IL USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.7504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7504

引用

页数：2